The United States has more than 36,000 doses of Jynneos vaccine available in stock
The United States has more than 36,000 doses of the Jynneos monkeypox vaccine immediately available in the strategic national reserve, according to the Department of Health and Human Services.
The Centers for Disease Control and Prevention are sending the vaccine to people who have had high-risk exposure to the virus in an effort to stop the further spread of the disease. The United States has identified 25 confirmed or anticipated cases of monkeypox cases in 12 states as of Friday.
The United States said so Nordic Bavarian, a Danish biotech company, to ship another 36,000 doses of Jynneos in the near future, an HHS spokesperson said. Bavarian Nordic holds more than 1 million US-owned doses and can fill 16.4 million more doses at the request of the federal government, the spokesperson said.
The global outbreak of monkeypox is the largest ever recorded outside of Africa. Nearly 800 confirmed cases of monkeypox in 27 countries have been reported to the World Health Organization. Most cases occur in Europe, particularly in Portugal, Spain and the United Kingdom.
The Food and Drug Administration approved Jynneos for adults 18 years of age and older at high risk of monkeypox or monkeypox in 2019. The two-dose vaccine is the only vaccine approved to specifically prevent monkeypox. However, the United States also has more than 100 million doses of the older generation ACAM2000 smallpox vaccine, the spokesperson said. ACAM2000 is made by Emerging BioSolutions
The United States has distributed 1,200 doses of Jynneos and ACAM2000 for people who have high-risk exposures to monkeypox, said Dr. Raj Panjabi, who heads the White House pandemic preparedness office, in a phone call with reporters Friday.
Although ACAM2000 was approved by the FDA in 2007 to prevent smallpox, the vaccine can also be used to protect against monkeypox under a CDC program. Monkeypox belongs to the same virus family as smallpox, although it is much milder.
The United States is also distributing an oral antiviral called tecovirimat that can be used to treat people infected with monkeypox, Panjabi said. Tecovirimat was the first pill approved by the FDA in 2018 for the treatment of smallpox, although it can also be used against monkeypox as part of a CDC program.
The CDC generally recommends Jynneos over ACAM2000, which can have serious side effects. ACAM2000 uses a live mild virus strain in the same family as monkeypox and smallpox that can still spread to the human body and to other people. The vaccine is given in a single dose that is scratched in the upper arm and the virus develops into a localized infection in the form of a blister.
The patient can spread the virus to other parts of the body if he scratches the bladder and then rubs the eye, for example, resulting in potential vision damage. The virus can also spread to other members of the patient’s family, which can be dangerous if a family member has a weak immune system or is pregnant or breastfeeding. The FDA has warned that it is important that people receiving ACAM2000 take proper care of the injection site so as not to spread the virus.
There are also large groups of people who should not receive ACAM2000 under CDC guidelines due to the risk of side effects. These people include pregnant or breastfeeding women, people with weak immune systems, individuals with skin conditions, and people with heart disease.
In pregnant women, the vaccine virus strain can spread to the fetus and cause stillbirth. People with weak immune systems run the risk of the virus spreading uncontrollably and causing a dangerous infection. Individuals with skin conditions such as eczema or atopic dermatitis are also at risk of the virus spreading to their skin and causing a life-threatening infection. ACAM2000 is also associated with a risk of heart inflammation, known as myocarditis and pericarditis.
The Jynneos vaccine has fewer side effects because the vaccine uses a mild viral strain that is unable to replicate in the human body, so it cannot spread.
ACAM2000 has demonstrated high levels of protection against monkeypox in animal models and is expected to provide 85% protection against virus disease, similar to previous versions of smallpox vaccines, according to Mark Slifka, an immunologist at Oregon Health. and Science University. Not much is known about Jynneos’ effectiveness because the vaccine is newer, but it has produced good antibodies in humans and is expected to protect against serious disease, according to Slifka.
The global outbreak of monkeypox has raised concern among public health officials because it is unusual for the virus to spread so much outside of West and Central Africa. Historically, the virus has spread from rodents to people in remote villages in Africa. However, according to Slifka, the virus now appears to be transmitted better between people through close physical contact.
WHO officials said last week that the virus has likely spread out of Africa unnoticed for some time, though it’s unclear for how long.
Most cases so far have been reported by gay and bisexual men who have developed systems and sought care at sexual health clinics, according to WHO. Health officials stressed that anyone can contract monkeypox through close physical contact. However, they said it is important to raise situational awareness in the LGBTQ community so that people can protect their health.
Dr Jennifer McQuiston, a CDC official, told reporters last week that most U.S. patients had a history of international travel in the 21 days prior to onset of symptoms, indicating they likely contracted the virus at the abroad. Although the CDC does not believe that monkeypox is spreading widely in the United States right now, health cannot rule out the possibility that it is spreading nationwide, McQuiston said.
Most people who contract monkeypox recover in two to four weeks without specific medical treatment, although the rashes that characterize the disease can be very painful, McQuiston said. The threat to public health is low right now, he told her.
Monkeypox usually starts with flu-like symptoms and rashes, then begins to spread over the body. The virus is mainly transmitted through skin-to-skin contact with these rashes. People can also catch monkeypox through shared bedding or clothing. People who have throat or mouth lesions can also spread the virus through respiratory droplets, although the disease is not easily transmitted this way, according to the CDC.
People with confirmed or suspected monkeypox infections should isolate themselves at home until state or local health departments say otherwise, according to the CDC. People with monkeypox should leave isolation only after the rashes have crusted, fallen off, and a new layer of skin has formed.